Follow up

Frequency No (%)

Increasing dose (600 - 800 mg)

10 (18.5)

Decreased dose (100 - 300)

5 (9.2)

Transformation to acute & accelerated phase

7 (13)

Death

4 (7)

Discontinued imatinib

9 (16)

Complete hematologic response

94%

Molecular response

46.8%

Refer for transplantation

2 (3.3)

Median duration follow up

44 (8 - 115) month

Unknown cases

6 (10)